Phase 4 N=54 The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine
Headache
Primary: Headache Following Intervention — 63.5; 43.5 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes
Diabetes Mellitus, Type 2
Primary: Subjects With Adverse Events as a Measure of Safety and Tolerability — 6; 8; 2; 3 Participants
Phase 4 N=806 A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
Asthma
Primary: Total Number of Asthma Exacerbations During Months 1-12 — 0.46; 0.81; 0.78 asthma exacerbations
Phase 4 N=291 Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Hypotension on Induction
Primary: Number of Participants With Interoperative Hypotension — 76; 95 Participants — p=0.03
N/A N=14 Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication
Low Back Pain
Primary: Pain — -1; -43 Percentage change from baseline to end
Phase 2 N=74 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Carcinoma, Renal Cell
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants
Phase 3 N=148 A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
Urinary Bladder, Overactive
Primary: Number of Participants With and Severity of Treatment-Emergent Adverse Events (TEAEs) — 72; 10; 20; 8 Participants
Phase 3 N=273 A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
Persistent Asthma
Primary: Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by…
Phase 3 N=713 Heart And Lung Failure - Pediatric INsulin Titration Trial
Heart Failure · Respiratory Failure
Primary: ICU-Free Days — 20; 19.4 Days
Phase 4 N=56 Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
Diabetes · Schizophrenia · Insulin Resistance
Primary: Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample — -49.65; 30.99 mg/dL
Phase 2 N=25 Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
Chronic Pancreatitis · Insulin Resistance · Normal or Mildly Abnormal Stool Fat Levels
Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants
Phase 3 N=302 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
N/A N=64 Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses
Myopia
Primary: Overall Comfort — 8.4; 8.7 units on a scale
Phase 2 N=21 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
B-Cell Prolymphocytic Leukemia · Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia
Primary: Overall Survival — 15 Participants
Phase 2 N=13 Nuedexta for the Treatment of Adults With Autism
Autism
Primary: Change in Maladaptive Behaviors — -6.62; -1.08 units on a scale